Follow on Google News
News By Tag
News By Place
Follow on Google News
Nova POC Creatinine/eGFR Method More Accurate Than Laboratory Method: Large Medical Center Study
By: Nova Biomedical
The study is unique because of its size, and because it is one of the first studies to compare accuracy of point-of-care creatinine/eGFR devices to the gold standard mGFR method in a chronic kidney disease (CKD) screening program. Other studies have only compared POC creatinine/eGFR devices to the laboratory and not to the true, iohexol measured GFR. This study was performed at University of Witwatersrand in Johannesburg, South Africa, internationally recognized for its research excellence. CKD affects over 10% of the population in South Africa and is growing at a disproportional rate. Lack of access to central laboratory services hinders the ability to implement effective screening programs to identify early stages of CKD and prevent progression. The study found StatSensor point-of-care creatinine/eGFR was more accurate than laboratory creatinine/eGFR when compared to mGFR and is practical for use as a CKD screening device in a resource limited setting.
Nova's StatSensor meter uses a miniaturized, single-use biosensor test strip and tiny capillary blood sample for blood creatinine/eGFR testing. Incorporating patented Multi-Well™ technology, StatSensor Creatinine enables simple, rapid, and accurate assessment of renal function by fingerstick capillary blood sampling at the point of care. "This study is very important to government health agencies, kidney or diabetes foundations, health maintenance organizations (HMOs) and other health agencies who want to implement screening programs for CKD" says Rick Rollins, Nova Marketing Manager. "In addition to superior accuracy, the study noted that StatSensor capillary sampling is preferred by patients and offers added benefit by eliminating the need for phlebotomy skills."
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacture of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Benelux, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.